 |
 |

Fracture Risk Among Breast Cancer Survivors
Results From the Womens Health Initiative Observational Study
Zhao Chen, PhD, MPH;
Michael Maricic, MD;
Tamsen L. Bassford, MD;
Mary Pettinger, MS;
Cheryl Ritenbaugh, PhD, MPH;
Ana Maria Lopez, MD;
David H. Barad, MD;
Margery Gass, MD;
Meryl S. LeBoff, MD
Arch Intern Med. 2005;165:552-558.
Background Breast cancer and its treatment may compromise bone health. We tested the hypothesis in the Womens Health Initiative Observational Study that postmenopausal survivors of breast cancer have a higher risk for fractures compared with women who have no cancer history.
Methods A prospective cohort (5.1 years follow-up) study design was used. Breast cancer survivors were women who reported a history of breast cancer (n = 5298). A reference group included women who had no cancer history at baseline (n = 80 848). Fracture occurrence was ascertained from annual self-reports. Hip fractures were confirmed by reviewing medical records.
Results After adjustment for age, weight, ethnicity, and geographic region of enrollment, the hazard ratios (HRs) of breast cancer survivors to women in the reference group were 0.93 (95% confidence interval [CI], 0.64-1.33) for hip; 1.36 (95% CI, 1.16-1.59) for forearm or wrist; 1.31 (95% CI, 1.19-1.43) for eligible fractures other than hip, vertebral, and forearm or wrist; and 1.31 (95% CI, 1.21-1.41) for these fractures combined. The increased risk for clinical vertebral fracture was statistically significant only among survivors who had a breast cancer diagnosis before age 55 years (HR, 1.78; 95% CI, 1.28-2.46). After adjusting for factors related to hormone levels, risk of fall, fracture history, medication use, comorbidity, and lifestyle, the increased risk for all fractures studied among survivors was reduced to 15% (HR, 1.15; 95% CI, 1.05-1.25).
Conclusions Postmenopausal survivors of breast cancer are at increased risk for clinical fractures. Preventions and therapeutic interventions are needed to reduce fracture risk in this large and growing population.
Author Affiliations: University of Arizona, Tucson (Drs Chen, Maricic, Bassford, Ritenbaugh, and Lopez); Fred Hutchinson Cancer Research Center, Seattle, Wash (Ms Pettinger); Albert Einstein College of Medicine, Bronx, NY (Dr Barad); University of Cincinnati, Cincinnati, Ohio (Dr Gass); Brigham and Womens Hospital, Harvard Medical School, Boston, Mass (Dr LeBoff).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Practical guidance for the management of aromatase inhibitor-associated bone loss
Hadji et al.
Ann Oncol 2008;19:1407-1416.
ABSTRACT
| FULL TEXT
Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Greenspan et al.
JCO 2008;26:2644-2652.
ABSTRACT
| FULL TEXT
Menopausal symptoms and adjuvant therapy-associated adverse events
Hadji
Endocr Relat Cancer 2008;15:73-90.
ABSTRACT
| FULL TEXT
Nonsteroidal Anti-inflammatory Drug Use and Serum Total Estradiol in Postmenopausal Women
Hudson et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:680-687.
ABSTRACT
| FULL TEXT
Recreational Physical Activity and Mammographic Breast Density Characteristics
Reeves et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:934-942.
ABSTRACT
| FULL TEXT
Breast Cancer and the Risk of Osteoporotic Fracture: A Paradox
Eastell
J. Clin. Endocrinol. Metab. 2007;92:42-43.
FULL TEXT
Prevention of Bone Loss in Survivors of Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Greenspan et al.
J. Clin. Endocrinol. Metab. 2007;92:131-136.
ABSTRACT
| FULL TEXT
Models for Delivering Survivorship Care
Oeffinger and McCabe
JCO 2006;24:5117-5124.
ABSTRACT
| FULL TEXT
Promoting Health and Physical Function Among Cancer Survivors: Potential for Prevention and Questions That Remain
Demark-Wahnefried et al.
JCO 2006;24:5125-5131.
ABSTRACT
| FULL TEXT
Meeting Report from Skeletal Complications of Malignancy IV: A symposium jointly sponsored by The Paget Foundation for Paget's Disease of Bone and Related Disorders, the National Cancer Institute, and the University of Virginia School of Medicine * April 28-30, 2005 in Bethesda, Maryland, USA
Vessella et al.
IBMS BoneKEy 2006;3:15-42.
FULL TEXT
|